A researcher reached out to us via email three years ago to ask why it appears that all racetrack veterinarians in Florida had heard about TB-500, yet no academic lab had ever ordered it. The answer lies in at the crossroads of peptide biochemistry, equine medicine and a regulatory breach that is still present in 2026. TB 500 is an artificial peptide and has a clearly defined mechanism of action, animal studies conducted decades ago and was deemed to be a banned substance according to the regulations adopted by WADA. Despite these merits, it has no completed human trials and is not approved by the FDA for any purpose.
If you have come to learn about the science, compare it with the BPC-157, go over dosages that researchers have used in their studies, or you want to understand the meaning of "99% purity" on the analysis certificate, you are in the right place. This product description is about TB-500 10 mg from US Peptide Labs which is only for research purposes.
TB-500 is a synthetic peptide that relates to the amino acids from the position 17 to the position 23 of the biological molecule Thymosin Beta-4 (TB-4), which is 43 amino-acids protein present in any type of human or animals cell. TB-500 includes a short amino-acid sequence of LKKTETQ that is vital for the binding of actin and functions of TB-4 protein. The possibility to synthesize this part of the protein is the reason TB-500 is easy to produce and used for many investigations as a separate substance instead of the whole protein TB-4.
TB-500 is a synthetic variant of the natural protein, TB4. The difference is important because it means they are not equivalent in research methods or in terms of regulation. Indeed TB4 is produced by blood cells and is present in the fluids during healing, where it functions to manage the cytoskeleton and tissue remodeling. Early characterization work found that the activity of TB4 to bind the actin was restricted to the central part of the peptide. This is similar to TB-500.
Researchers prefer the fragment over the complete protein because of the cost and stability involved in the synthesis process. Manufacturing a protein that comprises 43 amino acids is not as easy as it is for a peptide that has 7 amino acids. TB-500 is available in the market in the form of lyophilized powder, which is verified to have over 99% purity through HPLC, while the use of recombinant TB4 adds to the complexity. The bottom line behind “TB4 vs TB500” discussions in several forums is that TB4 is the naturally produced protein in the body while TB-500 is the synthetically manufactured fragment.
The TB-500 chemical operates mainly by attaching to the G-actin protein (monomeric actin) which manages the activities of the cytoskeleton during cell movement. When cells begin to move (to heal a cut or mend a tendon) they must quickly readjust their internal structure. TB-500 accomplishes this job by immobilizing G-actin and stabilizing the G-actin-thymosin balance in the cytoplasm.
Apart from its capacity to bind actin, research in cardiac models has also demonstrated that TB4 and its segments induce angiogenesis (which is the development of blood vessels) and inhibit signaling related to inflammation following an ischemic injury. The significance of this vascular aspect is related to the use of the substance in cardiovascular studies and is part of the question regarding cancer addressed in this article.
The mechanism has three main components, which are cell migration, angiogenesis, and anti-inflammatory signal transmission. Everything that happens afterwards (quicker wound healing, better tendon remodeling, and less local inflammation) is due to the above-mentioned effects.
TB-500 has a relatively short plasma half-life ranging from minutes to hours for the peptide. This is the norm for small peptides susceptible to immediate enzymatic breakdown. Nonetheless, these biological effects persist for a much longer time because the signaling pathways involved, especially those that are known to trigger increased cells’ movement and blood vessel formation, remain active even after the peptide is no longer circulating in the blood.
The pharmacokinetics underpinning this profile explains why two doses in a week are used in clinical trials instead of daily doses. The bioprocessing of twice-per-week doses ensures there is sufficient therapeutic signal without the need for cumbersome daily injection procedures. Additionally, the systemic effect does not require the peptide active ingredient to be in the bloodstream continuously.
The merits listed here are based on conclusions drawn from other published works. This means that the evidence is mainly taken from animal models and in vitro studies. There is no information concerning completed human trials of TB-500 anywhere. This is not the caveat at the end of the text – this is the first thing which a researcher should learn when making the evaluation of the compound.
TB-500's most famous use is repairing connective tissues. Studies using muscle injury models have shown that TB-500 speeds up the activation of satellite cells and reducing fibrosis compared to the control. Another key consideration with tendons and ligaments is that they heal slower than muscles, due to their relatively poor blood supply; thus, the angiogenic part of TB-500's action is of special importance because the formation of blood vessels can help transfer nutrients to tissues undergoing remodeling.
Research on equine tendons is where the evidence is the most robust in veterinary science. Racehorses frequently undergo injuries to their superficial digital flexor tendons which prompted the studies of TB-4 peptide products to appear starting from the beginning of the 21st century. It is the veterinary background of this knowledge that explains the use of the title "Tb-500 for horses" before most other applications. For a comparison of different substances studied in this field, see our tendon healing peptide guide section.
There is evidence from various animal and in vitro studies that TB4 fragments have anti-inflammatory properties by repressing the expression of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta in corneal wound models . This decrease in local inflammation is intuitively associated with a potential increase in the mobility of joints in terms of their movement range, although direct calculations of ranges of motion in animals are restricted.
The flexibility advantage which has been frequently quoted in research literature is mostly drawn from anti–inflammatory and tissue–remodeling studies instead of through direct assessment in controlled trials. Researchers must regard claims about flexibility as biologically plausible but unproven.
Cardiac investigation is one of the stronger fields of research. TB4 was found to increase the survival of cardiomyocytes, decrease the area of infarction and promote angiogenesis. When tested in skin wound healing models in animals, TB4 has accelerated re-epithelialization and reduced scar development. These are the two areas where the mechanistic evidence is the strongest, despite the clinical translation being still several years away.
There are many discussions regarding hair growth with TB-500 in online forums. The science does support that TB-4 is present in hair follicles and may assist in follicle turnover, but the evidence for TB-500 used for promoting hair growth is scant, essentially drawing on assumption based on findings with TB-4. There have been no publications on the use of the LKKTETQ peptide fragment which would allow its promoters to conduct studies to assess its effectiveness.
The founding of TB-500 in veterinary medicine is quite intriguing and often misconstrued. The fact that racehorses develop tendon injuries at such high rates has made them an early and viable subject for research in peptide-based repairs. Equine studies are not mere testimonials to the effectiveness of such treatments because they are based on controlled injuries and histological studies of tendon restructuring.
This document does not contain any amount of veterinary dosage guidance. Cited in the document is the equine research, but it is not offered for any current usage of this compound as a model.
In the case of rodent injury models, the differences that can be measured in terms of wound healing or tissue organization emerge often as early as one or two weeks after treatment initiation. When it comes to equine tendon studies, wound assessments usually occur every 4-8 weeks. The loading-phase procedure used in multiple design setups - 4-6 weeks of higher frequency treatment - provides a grounded biological basis for the application of the given methodology rather than being an arbitrary choice.
People who anticipate obtaining evidence in 3 days are probably basing this expectation on forum discussions instead of published studies. The truth is that quantifiable changes at the tissue level take weeks, not days.
The dosing details below outline the methods used in research papers and materials published by manufacturers of research supplies. It is not intended as a guideline for use in individual cases. TB-500 is only sold for laboratory use. Doses are given per sample being tested, as described in appropriate publications.
For a full interactive tool, use our peptide dosage calculator .
| Phase | Dose Per Administration | Frequency Per Week | Total Per Week | Duration |
|---|---|---|---|---|
| Loading | 2.5 mg. | 2x per week. | 5 mg. | 4-6 weeks. |
| Maintenance | 2.5 mg. | 1x per week. | 2.5 mg. | Ongoing per protocol. |
| Low-Dose Loading | 2 mg. | 2x per week. | 4 mg. | 4-6 weeks. |
| Low-Dose Maintenance | 2 mg. | 1x every 2 weeks. | 1 mg (avg). | Ongoing per protocol. |
The information available in the published literature shows that there is no research on daily dosing of TB-500, as the pharmacokinetic rationale is against it, because of the downstream biological effects that last longer than the plasma half-life of the substance. Therefore, using daily dosage is unnecessary and will only result in faster depletion of the vials without providing any real benefit in animal experiments. There are no variations in this approach that we have found in the protocols reviewed, since twice-weekly dosing is the only pattern that has been detected.
| Vial Size | Reconstitution Volume | Concentration | 2 mg Dose | 2.5 mg Dose |
|---|---|---|---|---|
| 5 mg | 1 ml bacteriostatic water. | 5 mg/ml (500 mcg/0.1 ml). | 0.4 ml / 40 units. | 0.5 ml / 50 units. |
| 5 mg | 2 ml bacteriostatic water. | 2.5 mg/ml (250 mcg/0.1 ml). | 0.8 ml / 80 units. | 1.0 ml / 100 units. |
| 10 mg | 2 ml bacteriostatic water. | 5 mg/ml (500 mcg/0.1 ml). | 0.4 ml / 40 units. | 0.5 ml / 50 units. |
| 10 mg | 3 ml bacteriostatic water. | 3.33 mg/ml (333 mcg/0.1 ml). | 0.6 ml / 60 units. | 0.75 ml / 75 units. |
The TB-500 10 mg vial from US Peptide Labs is the preferred format among researchers because they can produce a complete loading phase without needing several vials.
The research protocols include a loading phase of 4 to 6 weeks followed by a period of maintenance. The loading phase creates the biologic effect and the maintenance phase maintains it. There are no published studies about optimum cycle lengths in humans, so the 4-6 week duration is based on studies done in animal models where tissue changes can be measured. In some veterinary protocols, lengthier cycles are reported but very few studies have been done beyond 8 weeks in this case.
TB-500 protocols have emerged in the bodybuilding and sports recovery communities that quite closely resemble those used in research: 2-2.5 mg twice per week during loading and then frequency reduction. It must be stressed that this is not a clinically proven protocol for humans. It is necessary to understand the research supply context, since while TB-500 is available through research supply channels, it has not been approved for human use. Any use outside of a licensed research environment is in conflict with the intended purpose of the substance.
TB-500 is delivered on the basis of twice a week in a loading regimen in protocols according to the published documents. Since TB-500 has a systemic effect, the timing of the dose relative to exercising and injury has not been identified as a considerable factor by the investigators. The dosage is scheduled for administration with a spacing of 3-4 days in a week based on the twice-a-week protocol.
TB-500 comes in the form of a freeze-dried powder. Bacteriostatic water is introduced along the wall of the vial, instead of directly on to the powder pellet, to prevent the formation of bubbles and inactivation of the peptide. Mixing should be done gently instead of vortexing the solution. The reconstituted solution must be kept between 2-8 degrees Celsius and used according to the COA documentation. The lyophilized powder is to be stored before reconstitution in the refrigerator or freezer, and away from light and moisture.
A mistake that researchers often make in this process is pouring water too quickly or shaking the vial too much. Either one can result in denaturation of the peptide and cause the peptide concentration to decrease even if the solution looks clear.
The Get US Peptides dosage calculator is applied in the conversion of units of measurement, calculation of concentration, and planning of protocols. It is available for use without registration.
Subcutaneous injection of the lyophilized powder TB-500 provides the only available data for bioavailability. There have been no clinical pharmacokinetic studies done on other forms, such as capsules, nasal spray, and sublingual drops, even though they are commercially available.
It is imperative to highlight that TB-500 does not need to be injected at the site of damage. This is among the most essential distinctions TB-500 has from other research peptides. The mode of action is systemic: after entering the bloodstream, the effects of the peptide on the mobilization of cells and the development of blood vessels are not limited to the injection spot but occur throughout the body. The usual sites for subcutaneous injection in research – abdominal region and flank – can be used. There is also intramuscular injection in some research protocols, but subcutaneous injection is more frequently applied and more advantageous as technically less difficult.
No previous research has conducted a study on oral bioavailability of TB-500. According to pharmacology of peptides, they are expected to have low oral bioavailability due to proteolytic action in GI tract. Nasal delivery of peptides gives various results depending on molecular weight and formulation, but no measurements on TB-500 have been conducted. Tablets and capsules face the same issue of degradation as liquids administered orally.
| Form | Bioavailability (TB-500 specific) | Typical Research Dose | Best-Studied Use |
|---|---|---|---|
| Subcutaneous Injection | High (assumed, common for peptide medicines). | 2-2.5 mg per administration. | Standard research route. |
| Intramuscular Injection | High (assumed). | 2-2.5 mg per administration. | Muscle and tendon models. |
| Oral (capsule/pill) | No data; expected low. | Not established. | Not studied. |
| Nasal Spray | No data. | Not established. | Not studied. |
Studies conducted on animals mostly show a positive tolerability profile of TB-500 and TB4 at experimental doses. Most observations made in rodents are mild and temporary. In such related studies the following effects were reported: slight fatigue after administration, mild responses at injection sites, and temporary headache-like signs at higher doses. There is no evidence of toxicity to the organs at usual research doses in the literature.
While the animal safety findings are comforting within the doses studied, a direct extrapolation of this information indicates that human safety cannot be guaranteed. TB4 is an endogenous protein, thus giving TB-500 a theoretical advantage in terms of tolerability compared to entirely foreign substances. However, being termed "endogenous analogue" does not imply that it is risk-free in case of medically unregulated doses. Since there are no tests on humans, there is no clinical database of adverse events associated with TB-500 either. Scientists dealing with this drug must treat animal data as close to a hypothesis, rather than as a proof of safety for human application.
This mechanism of angiogenesis leads to a question: does TB-500 lead to new vessels formation, and does that mean that tumoral vascularization may be quicker? This issue was discussed in the literature on TB4. A review of thymosin beta-4 in cancer contexts mentioned that TB4 is overexpressed in different types of tumors and its effects (pro-migratory and pro-angiogenic) can contribute to tumor development. It does not mean, however, that TB-500 gives rise to cancer; it means that caution must be exercised when conducting research on people with already existing tumors or high cancer risk. The issue is still open for discussion in the literature.
| Pros | Cons |
|---|---|
| Well-characterized mechanism (actin binding, cell migration). | No human clinical trials completed. |
| Systemic effect - injection site flexibility. | Short plasma half-life; requires regular dosing. |
| Strong animal and veterinary data on angiogenesis in connective tissue models. | Angiogenic action raises theoretical cancer concerns. |
| No adverse effects observed in animal studies at research doses. | Not FDA approved; not permitted for human use. |
| Supplied as high-purity lyophilized powder (99.2% HPLC). | Prohibited by WADA - disqualifies competitive athletes. |
| Twice-weekly dosing; manageable protocol. | Oral and nasal forms have no bioavailability data. |
TB-500 has not received any FDA approval and none of the phases of the FDA IND clinical trial process have been completed by it as of 2026. It is a legitimate product in the US although it is strictly for laboratory research purposes which means it can be possessed, bought and used especially for research purposes but not commercially marketed as a food for humans by a physician or pharmacy.
There is nothing unclear about it. The substance under discussion is legally well-defined, as opposed to some other research chemicals that remain ambiguous in terms of their legal status. TB-500 hasn't gone through the FDA evaluation for any therapeutic purpose.
Yes. TB-500 is specifically forbidden by the World Anti-Doping Agency under the S2 category: Peptide Hormones, Growth Factors, Related Substances and Mimetics. The WADA prohibited list is updated on a yearly basis and TB-500 has always been on it. The NCAA uses the WADA prohibited list for most banned substance categories, as a result collegiate athletes in the US are affected by the same ban.
Published doping-detection research has created and proven techniques for detecting TB4 peptides in urine and blood matrices, confirming that anti doping laboratories can identify the substance. All professional, Olympic, and college level athletes should consider TB-500 to be on the danger list of positive test results that could end their careers.
It is worth noting that Section 503A of the Federal Food, Drug, and Cosmetic Act regulates compounding pharmacies that can only compound drugs using substances found in the FDA's approved list. TB-500 is not included on this list. As a result, the licensed compounding pharmacy is prohibited from compounding TB-500 for patient use, even in the event that a physician prescribes it. Accordingly, any substance sold to the public as "compound TB-500" does not comply with the FDA requirements.
In 2026, this distinction becomes relevant due to the FDA's active efforts to provide clarification on the boundaries concerning the 503A list. Those seeking TB-500 from credible sources should only deal with research supply dealers offering verifiable certificates of analysis and not through compounding sources which may mislead as to the status of said compound.
TB-500 is not one of the substances included in standard drug tests used in workplaces or clinics. These tests only screen for drugs like opioids, cannabinoids, amphetamines, and benzodiazepines, and TB-500 is not classified as any of these drugs. On the other hand, WADA-accredited anti-doping tests are designed to catch TB-500 in those getting tested. In this way, anyone working in the field of sports research should be worried about the fact that they may get caught using TB-500, unlike when taking part in a standard pre-employment urine test.
In the TB-500 market, there are suppliers who lack laboratory testing and those with laboratory test results from separate laboratories. In order for a claim of purity to be meaningful, it must be coupled with knowledge of the laboratory conducting the test. The product certificates provide evidence of 99.2% purity via HPLC and come from AxisPharm, an independent laboratory. There are six different lots certified by the laboratory with lot numbers inscribed on vials to confirm the product.
The vial of 10 mg is priced at $80.00 and provides enough injection for a complete 4-week load phase of 2.5 mg given twice per week, with some material left for the start of maintenance phase. Bulk price is $76.00 per piece for the purchase of 2 or more units, $72.00 for 5 or more units. Free shipping in the US for orders of over $70. It is shipped from the US facility and comes with tracking. Age verification is required.
In the market, the 5mg vial option is available, but it offers lower cost per milligram under full dosing protocols. If you are conducting research that involves numerous subjects or long-term projects, the healing and recovery collection offered by US Peptide Labs has bulk offerings.
A certificate of analysis (COA) for research peptides should minimally detail information related to HPLC purity percentage, molecular identity confirmation via mass spectrometer, batch number, and name of testing lab. Although purity via HPLC expresses how much of the desired compound is present compared to impurities contained in the sample, mass spectrometer confirmation is essential for verifying that the actual compound is indeed TB-500 instead of some other peptide of similar molecular weight. Please refer to our COA reading guide for more information on each field. AxisPharm COAs for TB-500 from US Peptide Labs include both HPLC purity and identity confirmation. Please see the COAs examples at uspeptidelabs.co/pages/quality-coas.
TB-500 prices in 2026 range from about $40 for a 5mg vial from suppliers with little documentation to $80-100 for a 10mg vial from reputable vendors. In relation to the costs resulting from improper material, the price differential between a vial with certification of analysis and an unverified one is not that impressive. Most researchers ought to expect the 10mg vial with 99.2% HPLC purity obtained from AxisPharm tests as the starting point when choosing a reliable supplier.
The biggest comparison sought in TB-500 studies also requires more sophistication than stating the obvious. The two peptides have overlapping areas of research though it employs different means, routes and research foundations.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Origin | Fragment of endogenous Thymosin Beta-4. | Synthetic fragment of human gastric juice protein BPC. |
| Main Methods | Actin adhesion, cell movement, angiogenesis. | Nitric oxide pathway, growth factor activity, tendon fibroblast activation. |
| Mode of Distribution | Systemic; injection site largely irrelevant. | More localized; some systemic effects documented. |
| Main Research Areas | Muscle, tendon, heart, wound healing. | Tendon, gut, muscle, nerve, bone. |
| Typical Research Dose | 2-2.5 mg twice weekly (loading). | 200-500 mcg daily or twice daily. |
| Evidence Base | Rodent, in vitro, equine veterinary. | Rodent, in vitro; broader injury-type coverage. |
| Human Trials | None for TB-500 specifically. | None completed. |
| WADA Status | Prohibited (S2). | Prohibited (S2). |
The reasoning behind the use of TB-500 with BPC-157 in research protocols is that both substances complement each other in their mechanisms of action. TB-500 leads to an increase in cell migration and the formation of new blood vessels throughout the body, while BPC-157 stimulates the local fibroblasts in the tendon and influences nitric oxide signaling. Therefore, these two agents are able to act on various levels of the process of tissue recovery at the same time, which is the main idea behind the BPC-157 / TB-500 Blend (10 mg, $85.00) offered by US Peptide Labs.
Researchers who wish to use a wider recovery peptide stack can make use of the KLOW blend (BPC-157 / GHK-Cu / TB-500 / KPV, $145.00), which is made up of four compounds that possess complementary mechanisms. The individual BPC-157 (10 mg, $65.00) is also available for protocols that seek to isolate the two peptides. See our combination protocol guide for research design details that concern peptide stacking.
Many researchers are curious if the preparation is the same as mixing the two peptides separately. The preparation, however, has a solid ratio which different vials allow independent dosage. The advantages of any of the approaches depend on the flexibility of the research methods used.
TB4 is an endogenous protein that has 43 amino acids. TB-500 is the synthetic fragment made up of seven amino acids (residues 17-23 – LKKTETQ). The main reason for using TB-500 is the ability to produce it in high purity, in a stable form, and to characterize it in the lab. The fact that TB-500 is a fragment does not imply that it is a degraded or lower version of TB4 – it is actually a biologically active fragment that can be produced artificially.
The concept of TB4 has been clinically explored (There are applications made for TB4 in cases related to heart problems and wound healing treatments) but TB-500, being the fragment, is used only in experimental procedures. When someone asks you about the differences between "TB4 and TB500," the answer is that TB4 is the protein entering clinical trial while TB-500 remains the synthetic fragment in practice used for experimental purposes.
In research environments, TB-500 is being researched for its ability to repair muscles, tendons, and ligaments; to help heal wounds; to aid recovery of cardiac tissue; and to reduce inflammation. The data has mostly been collected from experiments with rodents and in vitro studies, with some additional data gained from studies on racehorses in veterinary medicine. It has not been approved for human use.
Research protocols indicate that a dosage of 5mg per week (2.5mg twice per week) for 4-6 weeks is followed by a maintenance dosage of 2.5mg once a week or once in two weeks TB-500 is for laboratory research use only.
The research protocols published follow the twice-a-week approach during the loading stage. The peptide's short plasma half-life and the fact that its biological effects last longer means that resumptive twice-per-week dosing is justified by research protocols rather than daily dosing.
Bioavailability data of oral TB-500 have not been published. Specific peptides are susceptible to proteolytic degradation in the gastrointestinal tract before reaching the systemic circulation. Commercially, oral, capsule and nasal spray forms exist but have not been validated through pharmacokinetic studies in a peer-reviewed manner. Only the subcutaneous forms have demonstrated research evidence.
No, TB-500 is not approved by the FDA for any human or veterinary usage as of 2026 either. It is legally available as a research chemical only for laboratory purposes and cannot be prescribed, made or distributed for therapeutic purposes.
Animal studies carried out at test doses, have shown good tolerability of TB-500 with no reported organ toxicity. There is no published safety data for TB-500 in human clinical trials. The mechanism of action of angiogenesis raises concerns about the use of TB-500 in those with pre-existing malignancy. Just because we have established that something is “safe in rodent models,” does not imply that it is safe in humans or vice versa.
TB-500 operates through actin attachment and systemic cellular movement. In contrast, BPC-157 benefits from using nitric oxide pathways and stimulating local fibroblasts. Given that both compounds are under study for connective tissue repair, their mechanisms, while being different, allow for their combination in research setups. The above comparison shows both compounds side by side and the BPC-157 peptide library profile elaborates on TB-500’s mechanism in detail.
Based on consistent differences in mechanism, these two peptides are generally used together in studies. US Peptide Labs sells a premixed formulation of the two peptides. The decision to use the combined formulation or the individual compounds depends on whether or not dose regulation is necessary in the study. The article peptide healing injury guide discusses the factors to consider when designing a comparative study.
The criteria that are essential for researchers in the USA include the following: third-party HPLC purity checked above 99%, identity verification through mass spectrometry, lot-specific COA from a reputable laboratory and delivered to the US with tracking option, verification of the age. TB-500 10 mg vial at US Peptide Labs conform to all of these criteria: 99.2% HPLC purity, AxisPharm COA, lot number on the vial, free delivery to the US starting from $70, and requiring the age of 21. This is what all research providers must adhere to, and can be corroborated by the official documents.
View TB-500 10 mg at US Peptide Labs - 99.2% HPLC Purity, AxisPharm COA, Free US Shipping from $70